Diabetes, Antidiabetic Medications and Cancer Risk in Type 2 Diabetes: Focus on SGLT-2 Inhibitors
In the last decade, cancer became the leading cause of death in the population under 65 in the European Union. Diabetes is also considered as a factor increasing risk of cancer incidence and mortality. Type 2 diabetes is frequently associated with being overweight and obese, which also plays a role...
Main Author: | Mariusz Dąbrowski |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-02-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/4/1680 |
Similar Items
-
Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study
by: Chun-Ting Yang, et al.
Published: (2020-06-01) -
Pharmacogenetics of Type 2 Diabetes—Progress and Prospects
by: Yulia A. Nasykhova, et al.
Published: (2020-09-01) -
Combination therapy with SGLT2 inhibitors for diabetic kidney disease
by: Yuwen Cai, et al.
Published: (2020-07-01) -
SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
by: Honghong Zou, et al.
Published: (2017-05-01) -
Association of Antihyperglycemic Therapy with Risk of Atrial Fibrillation and Stroke in Diabetic Patients
by: Cristina-Mihaela Lăcătușu, et al.
Published: (2019-09-01)